BID

Vecima Networks Inc. Announces Initial Closing of Financing up to C$32 Million

Retrieved on: 
水曜日, 5月 29, 2024
Technology, Audio, Video, Software, Networks, Carriers and Services, Hardware, Toronto Stock Exchange, VCM, BID, Insider, Acquisition, Private, Corporation, Minority, Bankruptcy, Computershare, Funding, Multilateral, Vecima Networks, United States bankruptcy court, Hand, Indian stock exchange, TSX, Hearing, Security (finance)

Vecima anticipates closing an additional 215,300 Subscription Receipts (the “Additional Commitments” and together with the Brokered Private Placement and Non-Brokered Private Placement, the “Financing”) for gross proceeds of C$4,521,300 on May 31, 2024.

Key Points: 
  • Vecima anticipates closing an additional 215,300 Subscription Receipts (the “Additional Commitments” and together with the Brokered Private Placement and Non-Brokered Private Placement, the “Financing”) for gross proceeds of C$4,521,300 on May 31, 2024.
  • Raymond James Ltd. (“Raymond James” or the “Underwriter”) is acting as sole bookrunner and sole underwriter on the Brokered Private Placement and the Additional Commitments.
  • The Subscription Receipts are subject to the four-month hold period in accordance with applicable Canadian securities laws.
  • The Financing is subject to receipt of approval of the Toronto Stock Exchange.

Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress

Retrieved on: 
火曜日, 5月 28, 2024
Patient, European Renal Association, Pharmacokinetics, ATP, SAD, AKI, Acute kidney injury, Kidney disease, LOS, Dialysis, Index, DGF, BID, Therapy, Histology, Safety, NGAL, Chronic kidney disease, MD, Congress, Animal, CKD, Rat, Incidence, Biomarker, Kidney, Nanotechnology, Poster, TID, Hyperphosphatemia, Aes, Sevelamer, ERA, Pharmaceutical industry

LOS ALTOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that several presentations were delivered on the Company’s two product candidates, oxylanthanum carbonate (OLC) and UNI-494, at the 61st European Renal Association (ERA) Congress. OLC is a next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD). UNI-494 is a novel nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator initially targeting acute kidney injury (AKI).

Key Points: 
  • UNI-494 is a novel nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator initially targeting acute kidney injury (AKI).
  • This data compliments our previously reported data in the intravenous (IV) form of UNI-494.
  • The study concluded that UNI-494 is a potential candidate for prevention of delayed graft function (DGF) and other clinical conditions resulting from AKI.
  • Oxylanthanum Carbonate (OLC) Presentation Details:
    Results: This oral presentation evaluated the effects of tenapanor and OLC on phosphate excretion in rats.

Leading International Industry Trade Bodies Unite with Ad Net Zero, Green The Bid and AdGreen In Endorsement Of New Hard Drive Use Best Practice

Retrieved on: 
火曜日, 5月 21, 2024
UN, BID, Global warming potential, AICP, APA, ANA, IPA, Production, Carbon, United Nations Environment Programme, ISBA, Planet, FAQ, Insight, Advertising, AOP, TB, Renewable energy

The guidance, developed by Green The Bid, Ad Net Zero and AdGreen, aims to significantly reduce carbon emissions in production and lessen the burden on natural resources implicit in excessive hard drive usage.

Key Points: 
  • The guidance, developed by Green The Bid, Ad Net Zero and AdGreen, aims to significantly reduce carbon emissions in production and lessen the burden on natural resources implicit in excessive hard drive usage.
  • “The Hard Drive best practice came directly from our work with Green The Bid’s post production community, whose passion and diligence ultimately sparked this industry-wide consensus,” notes Green The Bid Co-Founder Jessie Nagel.
  • The film and television industries reuse hard drives, and we can, too,” said John Osborn, Director US at Ad Net Zero.
  • Detailed information on the agreed practice, its environmental impact, as well as a full FAQ, are available on the Ad Net Zero , Green The Bid and AdGreen websites.

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

Retrieved on: 
火曜日, 5月 21, 2024
Asian literature, IBD, DDW, Disease, Patient, Inflammation, UC, PDE4, Toxicity, DAI, BID, Trial of the century, DSS, AUC, Apremilast, Mouse, Vomiting, Psoriasis, CMO, Internal bleeding, Autoimmunity, Poster, Human body weight, Therapy, Dog, Model, Drinking water, Pharmaceutical industry

The poster is available on the Scientific Publications page of the Company’s website .

Key Points: 
  • The poster is available on the Scientific Publications page of the Company’s website .
  • PALI-2108 demonstrates similar target engagement to the PDE4 inhibitor, apremilast, which is approved for use in psoriasis and psoriatic arthritis.
  • Importantly, PALI-2108 exhibited a dose-dependent efficacy response in two DSS colitis mouse models, achieving efficacy comparable to doses of apremilast considered intolerable for human use in UC patients.
  • No systemic toxicity in dogs and large therapeutic window due to local activation.

Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
水曜日, 5月 15, 2024
Patient, Cohort, BID, Exercise, Therapy, Disease, Safety, Interstitial, Fibroblast, University of Giessen, Biomarker, Acquisition, Șaeș, Fibrosis, Research, IPF, Research and development, Administration, ALRN, Pharmaceutical industry

AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron” or the “Company”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron” or the “Company”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.
  • The Phase 1b study is ongoing, with topline results from the high-dose cohort expected in the third quarter of 2024.
  • Net Loss: Net loss for the quarter ended March 31, 2024, was $7.1 million, compared to $4.8 million for the corresponding quarter in 2023.
  • The basic and diluted net loss per share for the quarter ended March 31, 2024 was $0.86 compared to $1.05 for the quarter ended March 31, 2023.

Imperial Announces Normal Course Issuer Bid

Retrieved on: 
火曜日, 5月 14, 2024
Toronto Stock Exchange, BID, Imperial Metals, Plan, TSX

VANCOUVER, British Columbia, May 14, 2024 (GLOBE NEWSWIRE) -- Imperial Metals Corporation (“Imperial” or the “Company”) (TSX:III) announces the Toronto Stock Exchange (the “TSX”) has accepted the Company’s Notice of Intention to make a Normal Course Issuer Bid (the “Bid”) to be transacted through the facilities of the TSX or alternative Canadian trading systems.

Key Points: 
  • VANCOUVER, British Columbia, May 14, 2024 (GLOBE NEWSWIRE) -- Imperial Metals Corporation (“Imperial” or the “Company”) (TSX:III) announces the Toronto Stock Exchange (the “TSX”) has accepted the Company’s Notice of Intention to make a Normal Course Issuer Bid (the “Bid”) to be transacted through the facilities of the TSX or alternative Canadian trading systems.
  • Pursuant to the Bid, the Company may purchase up to 809,357 common shares, which represents 0.5% of the total 161,871,341 common shares of the Company issued and outstanding as of May 14, 2024.
  • The funding for any purchase pursuant to the Bid will be financed out of the working capital of the Company.
  • The maximum number of common shares sought and approved by the TSX under the terms of the previous Bid was 774,357.

Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
火曜日, 5月 14, 2024
Plasma, SOC, Risk, FDA, Ageing, Electrocardiography, Week, Fast Track, HCV, Kinetics, RNA, Research, QRS, Standard of care, QT, Bemnifosbuvir, Patient, QT interval, Infection, Cardiotoxicity, SVR4, Security (finance), Second generation, Administration, COVID-19, Food, Clinical trial, Viral, Safety, Hospital, Viral load, SVR, Doctor of Philosophy, NS5A, EASL, BID, Heart rate, Tax, NS5B, Immunodeficiency, Death, Cirrhosis, PR, Development, Pharmaceutical industry

BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.

Key Points: 
  • BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.
  • Final results from the 60-patient lead-in cohort confirmed a 98% SVR4 rate across all genotypes from 58 of 59 patients.
  • Topline results from all patients enrolled in the Phase 2 study are anticipated in the second half of 2024.
  • In April 2024, Atea presented Phase 1 data showing that bemnifosbuvir does not alter cardiac repolarization.

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer​

Retrieved on: 
木曜日, 5月 23, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Therapy, Sepsis, Patient, NAB, Retinal pigment epithelium, Bile, RAMP, Toxicity, ECOG, Febrile neutropenia, Verastem Oncology, Septic shock, BID, Clinical trial, Male, EDT, Avutometinib, Disease, Safety, Skin infection, Cancer, Pancreatic cancer, MMSc, Metastasis, ASCO, Anemia, Șaeș, Society, Eastern Cooperative Oncology Group, Mutation, Pulmonary embolism, Pneumoperitoneum, Webcast, BIW, Vomiting, DLT, Medicine, Annual general meeting, Phosphorus

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the initial interim safety and efficacy results from the ongoing RAMP 205 Phase 1/2 clinical trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in the first-line in patients with metastatic pancreatic cancer.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the initial interim safety and efficacy results from the ongoing RAMP 205 Phase 1/2 clinical trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in the first-line in patients with metastatic pancreatic cancer.
  • We continue to progress the study evaluating other dose and schedule regimens to determine the recommended Phase 2 dose in the trial,” said John Hayslip, M.D., chief medical officer of Verastem Oncology.
  • “We look forward to Verastem presenting their initial data from the Phase 1b/2a trial of avutometinib and defactinib in combination with standard care gemcitabine and Nab-paclitaxel in previously untreated metastatic pancreatic cancer at ASCO.
  • Verastem will hold an investor conference call and webcast on Friday, May 24 at 8:00 am EDT, to discuss these data.

Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

Retrieved on: 
水曜日, 5月 8, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, FXI, MTAP, Mutation, Safety, PARP, Pharmacokinetics, Carcinoma, Breast, STK11, BID, GBM, Glioblastoma, Culture, Journal, Novartis, Patient, Medicinal chemistry, Cancer, Collaboration, Clinical trial, Therapy, NSCLC, PRMT5, Pharmaceutical industry

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2024, and provided business highlights.

Key Points: 
  • Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2024, and provided business highlights.
  • Finally, we welcomed the newest member of our leadership team, Julie Carretero, as Chief Human Resources Officer.
  • Dose expansion is expected to initiate in the TNG462 phase 1/2 clinical trial in 2Q 2024.
  • General and administrative expenses were $10.7 million for the three months ended March 31, 2024, compared to $8.0 million for the same period in 2023.

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results

Retrieved on: 
火曜日, 5月 7, 2024
Research, FDA, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Net, Safety, Food, Irinotecan, CCNE1, PPP2R1A, Lung cancer, BID, ESMO, Adolescence, PLK4, PKMYT1, Data, Bristol Myers Squibb, Patient, WEE1, FBXW7, Biomarker, Clinical trial, Annual general meeting, Therapy, NSCLC, FOLFIRI, G&A, Pharmaceutical industry

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2024.
  • “This was a quarter of clinical progress as we await key, near-term data on a rich set of distinctive clinical approaches for our four wholly-owned compounds in 2024,” said Lloyd M. Segal, President and Chief Executive Officer of Repare.
  • We are seeing continuing trends of patient response and benefit, and we are on track to report the updated dataset in the fourth quarter of 2024.
  • The increase in revenue for the three-month period was primarily due to the $40.0 million Roche milestone achievement in the first quarter of 2024.